Abstract:The innate immune system provides the first line of defense against pathogen infection though also influences pathways involved in cancer immunosurveillance. The innate immune system relies on a limited set of germ line-encoded sensors termed pattern recognition receptors (PRRs), signaling proteins and immune response factors. Cytosolic receptors mediate recognition of danger damage-associated molecular patterns (DAMPs) signals. Once activated, these sensors trigger multiple signaling cascades, converging on the production of type I interferons and proinflammatory cytokines. Recent studies revealed that PRRs respond to nucleic acids (NA) released by dying, damaged, cancer cells, as danger DAMPs signals, and presence of signaling proteins across cancer types suggests that these signaling mechanisms may be involved in cancer biology. DAMPs play important roles in shaping adaptive immune responses through the activation of innate immune cells and immunological response to danger DAMPs signals is crucial for the host response to cancer and tumor rejection. Furthermore, PRRs mediate the response to NA in several vaccination strategies, including DNA immunization. As route of double-strand DNA intracellular entry, DNA immunization leads to expression of key components of cytosolic NA-sensing pathways. The involvement of NA-sensing mechanisms in the antitumor response makes these pathways attractive drug targets. Natural and synthetic agonists of NA-sensing pathways can trigger cell death in malignant cells, recruit immune cells, such as DCs, CD8+ T cells, and NK cells, into the tumor microenvironment and are being explored as promising adjuvants in cancer immunotherapies. In this minireview, we discuss how cGAS-STING and RIG-I-MAVS pathways have been targeted for cancer treatment in preclinical translational researches. In addition, we present a targeted selection of recent clinical trials employing agonists of cytosolic NA-sensing pathways showing how these pathways are currently being targeted for clinical application in oncology.

Potential Therapeutic Targets in the Process of Nucleic Acid Recognition: Opportunities and Challenges

Advancements in Tyrosine Kinase-Mediated Regulation of Innate Nucleic Acid Sensing.

Understanding nucleic acid sensing and its therapeutic applications

Revitalizing antitumor immunity: Leveraging nucleic acid sensors as therapeutic targets

Chemical regulation of the cGAS-STING pathway

Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles

Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies

Cytosolic Sensing of Aberrant DNA: Arming STING on the Endoplasmic Reticulum

The Recognition of and Reactions to Nucleic Acid Nanoparticles by Human Immune Cells

Nanoparticle targeting cGAS-STING signaling in disease therapy

Nucleic Acid Materials‐mediated Innate Immune Activation for Cancer Immunotherapy

Nucleic Acid Sensing Pathways in DNA Repair Targeted Cancer Therapy

DNA Sensing by Innate Immune Receptors (INM6P.408)

Regulation of the nucleic acid-sensing Toll-like receptors

Molecular and Structural Basis of DNA Sensors in Antiviral Innate Immunity

Activation of Innate Immunity by Therapeutic Nucleic Acids

Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects

DNA PAMPs as Molecular Tools for the cGAS-STING Signaling Pathways

Post-Translational Modifications of Proteins in Cytosolic Nucleic Acid Sensing Signaling Pathways

Mechanisms controlling nucleic acid-sensing Toll-like receptors

Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders